Bristol-Myers Squibb Company v. Cipla USA, Inc.
1:16-cv-00074
Overview
Parties
Defendant
Cipla Limited NPE (University / Research)
Represented By
1 Attorneys ListedADDRESS EXPIRED / UNKNOWN
ADDRESS EXPIRED / UNKNOWN, (302) 888-6800
Cipla USA, Inc. Operating Company
Represented By
3 Attorneys ListedADDRESS EXPIRED / UNKNOWN
ADDRESS EXPIRED / UNKNOWN, (302) 888-6800
Bristol-Myers Squibb Company NPE (Individual / Inventor)
Represented By
6 Attorneys ListedFarnan LLP
919 North Market Street, 12th Floor
Farnan LLP
919 North Market Street, 12th Floor
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 2 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → |
Bristol-Myers Squibb Company v. Mylan Pharmaceuticals, Inc.
Bristol-Myers Squibb Company v. Teva Pharmaceuticals USA Inc.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US6087383
Bisulfate salt of HIV protease inhibitor
|
Filed: 1998-12-21
Issued: 2000-07-11
|
Expired (Term Ended)
Expires: 2018-12-21
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.
Standard Statutory Term β No obviousness-type double patenting noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
3
Dispositive
0
Granted
0
Denied
0
Pending / Review
3
Motions by Category
Key Dispositive Motions & Rulings